BioSpace News Archive

Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s intellectual property portfolio made important advancements in Europe.

Indee Labs announces an exclusive marketing and distribution deal with Sunko Instruments in China for Hydropore Research Use Only.

StemCyte announced it has officially begun recruiting patients under a US Food and Drug Administration (FDA) approved Phase IIa human clinical trial in the United States.

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that on May 24, 2023 it received 510(k) clearance of its coactiv+™ Antimicrobial Wound Gel from the U.S. Food and Drug Administration (FDA) for the management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns.

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that all proposed resolutions submitted to the Annual General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST.

The Combined General Shareholders’ Meeting of Sanofi was held on May 25, 2023, under the chairmanship of Serge Weinberg.

NKGen Biotech Inc. (“NKGen”) today announced an upcoming poster presentation by its parent company, NKMax Co., Ltd., on preclinical and clinical data from a Phase I/IIa study of SNK01 in combination with cytotoxic chemotherapy in non-small cell lung cancer, at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held at the McCormick Place Convention Center in Chicago, Illinois from June 2-6, 2023.

Microbiome Insights Inc., a global leader in microbial sequencing and bioinformatic analysis, is pleased to announce the launch of its new metatranscriptomic sequencing services.

Oxurion NV (Euronext Brussels: OXUR) announced today that it has reached its enrollment target of 108 patients randomized in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) (KALAHARI trial).

Inventiva and Sino Biopharm, through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., announce that CTTQ received Investigational New Drug approval from the Chinese National Medical Products Administration on May 22nd 2023, and can now initiate the clinical development of Inventiva’s lead compound lanifibranor in mainland China.